Sarcoma is rare kind of cancer that occurs in the connective tissues of the body. Normal connective tissue include blood vessels, fat, nerves, muscles, deep skin tissues, bones, and cartilage. There are more than 50 types of sarcomas. However, they are mainly classified into two types: soft tissue sarcomas and bone sarcomas. They are further divided based on presumed cell of origin found in the tumor. Soft tissue sarcoma is the most common type of sarcoma, accounting for more than 80% of all sarcoma cases. Sarcoma affects all age groups but is more common in children. It is estimated that about 15% of cancer diagnosis in children are sarcomas. Rise in the incidence and prevalence of sarcoma, strong clinical pipeline of sarcoma drugs, rise in government initiatives toward orphan drug development, and increase in research and development expenditure are likely to fuel the growth of the global sarcoma market during forecast period. However, disappointing results of promising pipeline molecules, high cost of treatment and side effect associated with it, and stringent government regulations are estimated to hamper the growth of the global sarcoma market in in the coming years.
The global sarcoma market can be segmented based on type, treatment, and geography. Based on type, the sarcoma market can be segmented into soft tissue sarcoma and bone sarcoma. The soft tissue sarcoma segment is expected to hold a significant share of the market during forecast period, owing to high incidence and prevalence rate of soft tissue sarcoma. In terms of treatment, the global sarcoma market can be categorized into chemotherapy, surgery, radiation therapy, and others (stem cell therapy). The chemotherapy segment generally includes a combination of various anti-neoplastic drugs. The commonly used chemotherapeutics agents are dactinomycin, etoposide, irinotecan, doxorubicin, carboplatin, ifosfamide, vincristine, among others. The chemotherapy segment expected to account for a significant share of the market during forecast period due to high cost of chemotherapy and it preference as the first line therapy for the treatment of sarcoma. Rise in the incidence and prevalence of sarcoma, increase in demand for targeted therapy and personalized therapy, and significant pipeline molecules (such as afatinib and temsirolimus) are likely to propel the market in the near future. Furthermore, development of new products with improved efficacy as a part of growth strategies adopted by a number of players and strategic deals, mergers, and acquisitions in the sarcoma market are estimated to drive the market in the next few years.
In terms of geography, the global sarcoma market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to be a dominant region of the market, followed by Europe. The high incidence of sarcoma (around 15,000 new cases are diagnosed each year in the U.S.), growing awareness among people, increase in research and development expenditure, strong clinical pipeline, and well-established health care infrastructure contribute to the growth of the sarcoma market in North America. The market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period. The market is likely to be driven by India and China, owing to a significant patient base, increased government initiatives, and developing health care infrastructure. The market in Latin America and Middle East & Africa is anticipated to expand during the forecast period, owing to an increase in investments from market players in these regions and increase in prevalence of sarcoma.
The leading players in the global sarcoma market include Eli Lilly and Company, CytRx, Boehringer Ingelheim, Ovation Pharmaceuticals, Inc., Pfizer, Tracon Pharma, Karyopharm Therapeutics, Blueprint Medicines, Advenchen Laboratories, Oasmia Pharmaceutical, and Arog Pharmaceuticals.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.